November 8, 2025
Judo Bio’s Megalin-STRIKERs Achieve First Demonstration of Functional Pharmacodynamic Effects from Kidney Selective Gene Silencing in Non-Human Primates
read more
November 8, 2025
POSTER
American Society of Nephrology Kidney Week
The STRIKE Platform Enables Kidney-Selective Gene Silencing via Megalin-Mediated Uptake
read more
October 20, 2025
Judo Bio Presents Data Demonstrating Sustained, Kidney-Selective Gene Silencing Across Species
read more
October 20, 2025
POSTER
21st Annual Meeting of the Oligonucleotide Therapeutics Society
The STRIKE Platform Enables Kidney-Selective Gene Silencing via Megalin-Mediated Uptake
read more
September 19, 2025
Judo Bio Named to Endpoints 11 List of Biotech’s Most Promising Startups
read more
October 26, 2024
Judo Bio Presents Data Demonstrating Mechanism of Receptor-mediated Delivery of Oligonucleotides Resulting in Gene Silencing in the Kidney
read more
October 26, 2024
POSTER
American Society of Nephrology Kidney Week
Targeted Delivery of siRNA to Proximal Tubule Cells in Kidney
read more
October 11, 2024
Judo Bio to Present Data at the ASN Kidney Week 2024 Demonstrating Receptor mediated Delivery of Oligonucleotides to the Kidney
read more
October 7, 2024
Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney
read more
October 7, 2024
POSTER
20th Annual Meeting of the Oligonucleotide Therapeutics Society
Targeted delivery of siRNA to renal proximal tubule epithelial cells results in approximately 70% knockdown of target genes
read more
October 7, 2024
Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO
read more

We're honored that our progress has been recognized:

Back to Top